학술논문

Protective action of doxycycline against diabetic cardiomyopathy in rats.
Document Type
Article
Source
British Journal of Pharmacology. Dec2008, Vol. 155 Issue 8, p1174-1184. 11p. 1 Diagram, 1 Chart, 5 Graphs.
Subject
*ANTIBIOTICS
*DIABETES complications
*CARDIOMYOPATHIES
*METALLOPROTEINASES
*REACTIVE oxygen species
*LABORATORY rats
*PHARMACOLOGY
Language
ISSN
0007-1188
Abstract
Background and purpose:Reactive oxygen and nitrogen species play an important role in the development of diabetic cardiomyopathy. They can activate matrix metalloproteinases (MMPs), and MMP-2 in particular is known to mediate early consequences of oxidative stress injury in the heart. Therefore, we investigated the role of MMP-2 and the effect of the MMP inhibitor doxycycline on the changes of heart function caused by diabetes.Experimental approach:Using streptozotocin-induced diabetic rats, we evaluated the effect of doxycycline on both mechanical and electrical function of isolated hearts, papillary muscle and cardiomyocytes.Key results:Doxycycline abolished the diabetes-induced depression in left ventricular developed pressure and the rates of changes in developed pressure in isolated hearts and normalized the prolongation of the action potential in papillary muscles. In cardiomyocytes isolated from doxycycline-treated diabetic rats, the altered kinetic parameters of Ca2+ transients, depressed Ca2+ loading of sarcoplasmic reticulum and basal intracellular Ca2+ level, and the spatio-temporal properties of Ca2+ sparks were significantly restored. Gelatin zymography and western blot data indicated that the diabetes-induced alterations in MMP-2 activity and protein level, level of tissue inhibitor of matrix metalloproteinase-4 and loss of troponin I were restored to control levels with doxycycline.Conclusions and implications:Our data suggest that these beneficial effects of doxycycline on the mechanical, electrical and biochemical properties of the diabetic rat heart appear, at least in part, to be related to inhibition of MMP activity, implying a role for MMPs in the development of diabetic cardiomyopathy.British Journal of Pharmacology (2008) 155, 1174–1184; doi:10.1038/bjp.2008.373; published online 22 September 2008 [ABSTRACT FROM AUTHOR]